TSX gains after CPI shows US inflation rose 3%
Director Arthur F. Golden of Turn Therapeutics Inc (NASDAQ:TTRX) recently purchased 20,202 shares of common stock at $4.95, according to a Form 4 filing with the Securities and Exchange Commission. The transaction, which occurred on October 23, 2025, amounted to a total investment of $99,999. The purchase comes as the stock trades near its 52-week low of $4.81, with InvestingPro data showing a significant decline from its peak of $26.50.
Following the purchase, Golden directly owns 30,202 shares of Turn Therapeutics. The company, currently valued at $117 million, shows mixed signals with a strong current ratio of 3.2 but faces profitability challenges. InvestingPro analysis reveals 5 additional key insights about TTRX’s financial health and market position.
In other recent news, Turn Therapeutics has announced the appointment of Arthur Golden to its Board of Directors. Golden brings extensive experience with over 40 years in corporate law, governance, and strategic advisory work. He is currently a Senior Counsel at Davis Polk & Wardwell LLP and has previously spent more than four decades as a partner at the firm. Additionally, Golden has just completed a 24-year tenure as a Director at Emerson Electric, where he chaired the Corporate Governance and Finance Committees and was a member of the Executive Committee. These recent developments are part of Turn Therapeutics’ ongoing efforts to strengthen its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.